CMN Markets February 2022 | CRISPR Stocks and...
Mar. 3, 2022
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Kyverna Therapeutics
Company Type: Therapeutic development
Main focus: Developing engineered cell therapies to treat autoimmune diseases
Company stage: Clinical
Diseases: Stiff person syndrome, Myasthenia gravis, Lupus nephritis, Multiple sclerosis, Systemic sclerosis, and other autoimmune diseases
Genome-editing tool: CRISPR-Cas9
Funding stage: Series B
Location: Emeryville, California, USA
Website: kyvernatx.com
Pipeline: kyvernatx.com/platform-pipeline/pipeline/
Partners: Intellia Therapeutics
Kyverna Therapeutics is a clinical-stage biotechnology company focused on the development of gene-edited cell therapies to treat autoimmune diseases. The company’s scientific approach involves editing T cells to recognise, attack, and destroy B cells to achieve an immune system reset in patients with B cell driven autoimmune diseases. Kyverna is investigating the use of CRISPR-Cas9-mediated gene edits in a pre-clinical study of KYV-201, an allogeneic anti-CD19 CAR T-cell therapy, to improve drug efficacy and safety. The company has licensed Intellia Therapeutics' CRISPR-Cas9 technology for the development of KYV-201.
